A systematic description of MLL fusion gene formation

Rebecca L. Wright, Andrew T M Vaughan

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Rearrangements of the MLL gene involve multiple partners and are implicated in both therapy related acute leukemia [tAL] and infant acute leukemia. For these diseases, recently compiled clinical data confirms an elevated frequency of such breakpoints within a 4. kb tract between exon 11 and a region of structural instability adjacent to exon 12. Linked primarily to cases of tAL, interference with topoisomerase II activity may either contribute to the initial DNA lesion directly or indirectly by, for example, providing a physical block to transcription progression. Alternatively, sites of fragmentation may be mis-repaired, guided by intergenic spliced transcripts of the participating genes. Co-transcription of MLL and potential fusion partners may provide the localization that enhances the probability of gene interaction. An indirect role for the leukemogenic activity of topoisomerase II inhibitors would imply that the negative consequences of their use may be separated from their therapeutic effects.

Original languageEnglish (US)
Pages (from-to)283-291
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume91
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Gene Fusion
Leukemia
Exons
Topoisomerase II Inhibitors
Type II DNA Topoisomerase
Gene Rearrangement
Sexual Partners
Therapeutic Uses
Genes
DNA
Therapeutics

Keywords

  • Acute leukemia
  • AICDA
  • MLL
  • Recombinome
  • Topoisomerase II
  • Transcription factory
  • Translocation

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

A systematic description of MLL fusion gene formation. / Wright, Rebecca L.; Vaughan, Andrew T M.

In: Critical Reviews in Oncology/Hematology, Vol. 91, No. 3, 2014, p. 283-291.

Research output: Contribution to journalArticle

@article{22100382be2c4920b4b99d9f00248594,
title = "A systematic description of MLL fusion gene formation",
abstract = "Rearrangements of the MLL gene involve multiple partners and are implicated in both therapy related acute leukemia [tAL] and infant acute leukemia. For these diseases, recently compiled clinical data confirms an elevated frequency of such breakpoints within a 4. kb tract between exon 11 and a region of structural instability adjacent to exon 12. Linked primarily to cases of tAL, interference with topoisomerase II activity may either contribute to the initial DNA lesion directly or indirectly by, for example, providing a physical block to transcription progression. Alternatively, sites of fragmentation may be mis-repaired, guided by intergenic spliced transcripts of the participating genes. Co-transcription of MLL and potential fusion partners may provide the localization that enhances the probability of gene interaction. An indirect role for the leukemogenic activity of topoisomerase II inhibitors would imply that the negative consequences of their use may be separated from their therapeutic effects.",
keywords = "Acute leukemia, AICDA, MLL, Recombinome, Topoisomerase II, Transcription factory, Translocation",
author = "Wright, {Rebecca L.} and Vaughan, {Andrew T M}",
year = "2014",
doi = "10.1016/j.critrevonc.2014.03.004",
language = "English (US)",
volume = "91",
pages = "283--291",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - A systematic description of MLL fusion gene formation

AU - Wright, Rebecca L.

AU - Vaughan, Andrew T M

PY - 2014

Y1 - 2014

N2 - Rearrangements of the MLL gene involve multiple partners and are implicated in both therapy related acute leukemia [tAL] and infant acute leukemia. For these diseases, recently compiled clinical data confirms an elevated frequency of such breakpoints within a 4. kb tract between exon 11 and a region of structural instability adjacent to exon 12. Linked primarily to cases of tAL, interference with topoisomerase II activity may either contribute to the initial DNA lesion directly or indirectly by, for example, providing a physical block to transcription progression. Alternatively, sites of fragmentation may be mis-repaired, guided by intergenic spliced transcripts of the participating genes. Co-transcription of MLL and potential fusion partners may provide the localization that enhances the probability of gene interaction. An indirect role for the leukemogenic activity of topoisomerase II inhibitors would imply that the negative consequences of their use may be separated from their therapeutic effects.

AB - Rearrangements of the MLL gene involve multiple partners and are implicated in both therapy related acute leukemia [tAL] and infant acute leukemia. For these diseases, recently compiled clinical data confirms an elevated frequency of such breakpoints within a 4. kb tract between exon 11 and a region of structural instability adjacent to exon 12. Linked primarily to cases of tAL, interference with topoisomerase II activity may either contribute to the initial DNA lesion directly or indirectly by, for example, providing a physical block to transcription progression. Alternatively, sites of fragmentation may be mis-repaired, guided by intergenic spliced transcripts of the participating genes. Co-transcription of MLL and potential fusion partners may provide the localization that enhances the probability of gene interaction. An indirect role for the leukemogenic activity of topoisomerase II inhibitors would imply that the negative consequences of their use may be separated from their therapeutic effects.

KW - Acute leukemia

KW - AICDA

KW - MLL

KW - Recombinome

KW - Topoisomerase II

KW - Transcription factory

KW - Translocation

UR - http://www.scopus.com/inward/record.url?scp=84904668231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904668231&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2014.03.004

DO - 10.1016/j.critrevonc.2014.03.004

M3 - Article

C2 - 24787275

AN - SCOPUS:84904668231

VL - 91

SP - 283

EP - 291

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -